Their Hsp90β-selective inhibitors were claimed to be cytotoxic to cancer cells while not inducing a HSR, thereby overcoming the detriments associated with pan-Hsp90 inhibition (Mishra et al. 2021b). This evidence concerns the gene HSP90AB1 and cancer.